← All trial listings Recruiting

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

ClinicalTrials.gov ID NCT07300969 · A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)

Check if you may qualify View the official record

At a glance

Status
Recruiting
Condition
Major Depressive Disorder (MDD)
Phase
Phase 2
Ages
18 Years to 75 Years
Sex
All
Healthy volunteers
Not accepted
What is being studied
DT-101 (drug); DT-101 (drug); Placebo (drug)
Sponsor
Draig Therapeutics Ltd
Target enrollment
300 participants
Study sites
43 open in Arkansas, Bulgaria, California, Czechia, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada, New Jersey, New York, Pennsylvania, Poland, Texas, United Kingdom, Washington
Start date
2025-12-16
Primary completion
2027-08

Common questions

Is NCT07300969 still recruiting?

ClinicalTrials.gov lists this trial as recruiting (checked 5 October 2026). It has 43 open or upcoming sites.

Who can take part in NCT07300969?

The record lists people aged 18 to 75 years with major depressive disorder (mdd). The study team decides who is eligible, and the full criteria are on this page and in the official record.

Where is NCT07300969 running?

43 sites in Arkansas, Bulgaria, California, Czechia, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada, New Jersey, New York, Pennsylvania, Poland, Texas, United Kingdom, Washington, according to ClinicalTrials.gov.

What is being studied in NCT07300969?

It is a Phase 2 trial. The record lists these interventions: DT-101, DT-101 and Placebo. The sponsor is Draig Therapeutics Ltd.

How many people will NCT07300969 enroll?

The record gives a target of 300 participants.

How do I sign up for NCT07300969?

Use "Check if you may qualify" on this page to answer a few screening questions, or contact the study team listed on ClinicalTrials.gov.

About this trial

From the ClinicalTrials.gov record.

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Where it's running

SiteCityStateStatus
Draig Clinical SiteBentonvilleArkansasRecruiting
Draig Clinical SiteLittle RockArkansasRecruiting
Draig Clinical SiteOceansideCaliforniaRecruiting
Draig Clinical SiteSan DiegoCaliforniaRecruiting
Draig Clinical SiteTorranceCaliforniaRecruiting
Draig Clinical SiteMiamiFloridaRecruiting
Draig Clinical SiteNew Port RicheyFloridaRecruiting
Draig Clinical SiteOrlandoFloridaRecruiting
Draig Clinical SiteAtlantaGeorgiaRecruiting
Draig Clinical SiteDecaturGeorgiaRecruiting
Draig Clinical SiteGaithersburgMarylandRecruiting
Draig Clinical SiteWatertownMassachusettsRecruiting
Draig Clinical SiteFlowoodMississippiRecruiting
Draig Clinical SiteLas VegasNevadaRecruiting
Draig Clinical SiteMarltonNew JerseyRecruiting
Draig Clinical SiteNew YorkNew YorkRecruiting
Draig Clinical SiteMediaPennsylvaniaRecruiting
Draig Clinical SiteAustinTexasRecruiting
Draig Clinical SiteAustinTexasRecruiting
Draig Clinical SiteDeSotoTexasRecruiting
Draig Clinical SiteRichardsonTexasRecruiting
Draig Clinical SiteWichita FallsTexasRecruiting
Draig Clinical SiteBellevueWashingtonRecruiting
Draig Clinical SiteKazanlakBulgariaRecruiting
Draig Clinical SitePlovdivBulgariaRecruiting
Draig Clinical SiteSofiaBulgariaRecruiting
Draig Clinical SiteSofiaBulgariaRecruiting
Draig Clinical SiteSofiaBulgariaRecruiting
Draig Clinical SiteSofiaBulgariaRecruiting
Draig Clinical SiteVratsaBulgariaRecruiting
Draig Clinical SiteOstravaCzechiaRecruiting
Draig Clinical SitePragueCzechiaRecruiting
Draig Clinical SiteŘíčanyCzechiaRecruiting
Draig Clinical SiteGdanskPolandRecruiting
Draig Clinical SiteKatowicePolandRecruiting
Draig Clinical SitePoznanPolandRecruiting
Draig Clinical SiteChesterUnited KingdomRecruiting
Draig Clinical SiteEastbourneUnited KingdomRecruiting
Draig Clinical SiteGlasgowUnited KingdomRecruiting
Draig Clinical SiteLondonUnited KingdomRecruiting
Draig Clinical SiteLondonUnited KingdomRecruiting
Draig Clinical SiteNottinghamUnited KingdomRecruiting
Draig Clinical SiteOxfordUnited KingdomRecruiting
Full eligibility criteria (from the record)

Inclusion Criteria: * The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent * Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent. * Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022). Exclusion Criteria: * Pregnant or breastfeeding or plans to become pregnant during the study. * Unstable medical condition or unstable chronic disease. * Significant neurological abnormality. * History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening. * History of seizure. * In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.

Other recruiting trials: Depression (major depressive disorder) clinical trials · Depression (major depressive disorder) clinical trials in Texas

This listing shows only what the public ClinicalTrials.gov record NCT07300969 says, last updated there on 2026-08-26. It was checked against the registry on 5 October 2026. Taking part is voluntary, and the study team decides who is eligible. For the most current details, see the official record.